A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Purpose of Study

• The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: TriHealth Inc.

Criteria

• Eligibility Criteria

• Participants will be 16 years or older.

• COVID-19 infection demonstrated via SARS-CoV-2 PCR testing.

• Admitted to the hospital for treatment of Covid 19.

• Patients must have severe/high risk disease as defined by the presence of any one of the following:

Respiratory frequency ≥ 25/minute Oxygen saturation ≤ 93% on room air Partial pressure of arterial oxygen to fraction of inspired oxygen ration < 300, or pulse oximetric saturation to fraction of inspired oxygen ratio < 315.

Lung infiltrates > 50% within 24-48 hours of admission on Chest X-Ray or, Ferritin > 1000 or absolute lymphocyte count < 600 or D-Dimer > 1.00

• ABO Blood Type available.

• Pregnant women will be permitted to participate in this study.

• Exclusion criteria

• Previous history of life threatening or severe adverse reactions to transfusion blood products..